Key Takeaways
- The standard starting dose in phase 3 trials is 0.25 mg subcutaneously once weekly, escalated every four weeks.
- The target maintenance dose is 2.4 mg once weekly; the phase 2 maximum tested was 4.5 mg weekly, but 2.4 mg was selected on benefit-risk grounds.
- Cagrilintide's half-life is approximately seven days, which is why once-weekly dosing achieves near-steady-state receptor occupancy.
- In the CagriSema phase 3 program, the combination of cagrilintide 2.4 mg plus semaglutide 2.4 mg produced mean body weight loss of approximately 22.7% at 68 weeks (REDEFINE 1 trial data presented at ADA 2024).
- Cagrilintide is not FDA approved as of May 2026 and is not legally available as a compounded preparation in the US under current guidance.
What is the correct cagrilintide dosage?
Table of Contents
- Cagrilintide dosage chart and escalation schedule
- Mechanism and pharmacokinetics behind the dose numbers
- CagriSema combination dosing
- Evidence ledger: what the trial data actually show
- What most dosage pages get wrong
- Head-to-head: cagrilintide vs. pramlintide vs. semaglutide alone
- Side effects and dose adjustment rules
- Label and COA literacy: how to evaluate what you are actually getting
- FAQ
- Sources
What does the cagrilintide dosage chart look like?
The escalation schedule below is drawn directly from the phase 2 dose-ranging trial (Lau et al., Lancet 2021) and the phase 3 CagriSema protocol disclosures. It is investigational. It is not a prescription recommendation.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Week | Cagrilintide dose (weekly SC) | Clinical trial step name | Primary rationale |
|---|---|---|---|
| 1-4 | 0.25 mg | Initiation | GI tolerability establishment |
| 5-8 | 0.5 mg | Step 2 | Assess nausea threshold |
| 9-12 | 1.0 mg | Step 3 | Approaching half maintenance |
| 13-16 | 1.7 mg | Step 4 | Near-maintenance receptor loading |
| 17+ | 2.4 mg | Maintenance | Target phase 3 dose |
Dose delay rule in trials: Any step could be held for an additional four weeks if nausea or vomiting was ongoing. Participants who could not tolerate escalation were permitted to maintain at a lower step (commonly 1.7 mg or 1.0 mg) rather than discontinue entirely.
What mechanism justifies this specific dose range?
Cagrilintide is a synthetic analogue of human amylin (islet amyloid polypeptide, IAPP), modified with a C20 fatty-diacid moiety attached via a linker to lysine at position 26. This fatty-acid conjugation enables albumin binding, extending the half-life from the roughly 90-minute plasma half-life of native amylin to approximately seven days in humans, based on pharmacokinetic data reported in the phase 1 and phase 2 programs.
Receptor targets: Cagrilintide activates the calcitonin receptor (CTR) and CGRP receptor complexes, particularly AMY1, AMY2, and AMY3 receptor subtypes (CTR co-assembled with receptor activity-modifying proteins RAMP1, RAMP2, RAMP3). Key central sites include the area postrema (AP) and nucleus tractus solitarius (NTS), which lack the blood-brain barrier and are directly accessible to circulating peptides.
Why weekly dosing achieves sustained effect: With a seven-day half-life and once-weekly injection, trough plasma concentrations remain well above the estimated EC50 for satiety signaling throughout the dosing interval. Steady-state is reached after approximately four to five doses (four to five weeks). The four-week escalation steps are timed to allow the system to equilibrate at each steady-state level before the next increase.
Why 2.4 mg and not 4.5 mg: The phase 2 trial (n=706, Lau et al., Lancet 2021) showed that weight loss increased incrementally from 0.3 mg to 2.4 mg but the additional benefit at 4.5 mg was modest relative to a meaningfully higher rate of GI adverse events. The 2.4 mg dose produced a placebo-subtracted weight reduction of approximately 10.8 percentage points at 26 weeks in that trial, with an acceptable tolerability profile. This justified selecting 2.4 mg for phase 3.
What the mechanism does NOT prove: Receptor activation in the AP and NTS does not guarantee the translated magnitude of weight loss seen in controlled trials will replicate outside those conditions (calorie-controlled diet, exercise counseling, regular contact with trial staff). Central amylin signaling is one input into energy homeostasis; it does not override all compensatory mechanisms.
How does CagriSema change the dosing picture?
CagriSema is a fixed-ratio co-formulation combining cagrilintide 2.4 mg and semaglutide 2.4 mg in a single weekly subcutaneous injection. Each component escalates within the same pen device. The REDEFINE 1 trial (phase 3, n=3,417, presented at ADA 2024) used this combination and reported a mean weight reduction of approximately 22.7% at 68 weeks in people with obesity without type 2 diabetes, compared to roughly 11.8% for semaglutide 2.4 mg alone in the same program.
The combination rationale is receptor complementarity: semaglutide acts primarily via GLP-1 receptors (liver, pancreas, CNS), while cagrilintide acts via amylin/calcitonin receptors. The two pathways converge on appetite and gastric emptying but through distinct circuits, which may explain the additive weight-loss signal.
Dosing the components separately: Outside of a registered trial or approved product, combining separately sourced cagrilintide and semaglutide introduces uncharacterized pharmacokinetic and pharmacodynamic interaction risks. There are no published data on safety or efficacy of self-mixed combinations using compounded or gray-market materials.
Evidence ledger: what do the trial data actually show?
| Claim | Best evidence type | Sample / detail | Effect direction | Confidence |
|---|---|---|---|---|
| 2.4 mg weekly produces clinically meaningful weight loss in adults with obesity | Phase 2 RCT (Lau et al., Lancet 2021) | n=706, 26 weeks | Positive (~10.8% placebo-subtracted) | Moderate |
| CagriSema 2.4/2.4 mg superior to semaglutide 2.4 mg alone for weight loss | Phase 3 RCT (REDEFINE 1, ADA 2024 presentation) | n=3,417, 68 weeks | Positive (~22.7% vs ~11.8%) | Moderate-High (full publication pending) |
| 0.25 mg starting dose limits early GI side effects | Phase 2 dose-finding (Lau et al., 2021) + phase 3 protocol | Multiple arms | Positive (lower dropout at low start) | Moderate |
| Half-life approximately 7 days supports weekly dosing | Phase 1 PK studies (Novo Nordisk IND data, cited in phase 2 paper) | Healthy volunteers | Confirmed | High |
| 4.5 mg dose provides no meaningful additional weight loss vs. 2.4 mg | Phase 2 RCT dose-response analysis | n=706 | Plateau effect at 2.4 mg | Moderate |
| Long-term cardiovascular outcomes improved vs. placebo | No published CV outcomes trial yet | REDEFINE 2 ongoing | Unknown | Very low |
What most cagrilintide dosage pages get wrong
Most pages present the escalation table and stop. Here is what they omit:
1. The "maintenance dose" is still investigational
The 2.4 mg figure comes from a clinical trial, not from an approved label. There is no approved label. Presenting 2.4 mg as a "recommended dose" implies a regulatory endorsement that does not yet exist.
2. Purity and peptide identity cannot be assumed in gray-market material
Cagrilintide requires C20 fatty-diacid conjugation at a specific lysine residue. This chemistry is not trivially replicated. Analysis of gray-market GLP-1 peptides by multiple academic groups has found incorrect molecular weights, missing fatty-acid chains, and bacterial endotoxin contamination. None of these defects are detectable by appearance or smell. Without a mass-spectrometry-verified certificate of analysis from an ISO-accredited lab, purity is unknown. This matters for dosing because an impure or partially conjugated product has an unpredictable half-life and receptor affinity.
3. Reconstitution is not standardized for cagrilintide outside trials
In registered trials, cagrilintide was supplied as a solution in a pre-filled pen at a defined concentration. Lyophilized (powder) vials of cagrilintide are not part of any published investigational protocol. If a lyophilized product is encountered, the diluent type, concentration after reconstitution, and pH compatibility are unvalidated. Injecting an incorrect concentration shifts every dose calculation.
4. Injection-site concentration gradients are not interchangeable
Subcutaneous absorption rate differs slightly by site (abdomen vs. thigh vs. upper arm). For a seven-day half-life peptide this difference is smaller than it would be for a short-acting compound, but it is not zero. Rotating injection sites is recommended to prevent lipohypertrophy, which itself reduces absorption reproducibility over time.
How does cagrilintide compare to its real alternatives?
| Factor | Cagrilintide 2.4 mg QW | Pramlintide (Symlin) | Semaglutide 2.4 mg QW (Wegovy) |
|---|---|---|---|
| Approval status | Phase 3, no approval | FDA approved (diabetes adjunct) | FDA approved (obesity) |
| Dosing frequency | Once weekly | 2-3x daily with meals | Once weekly |
| Weight loss (monotherapy, ~68 wk) | ~8-10% (monotherapy estimate from phase 2) | 1-3% in trials as adjunct | ~15% (STEP 1 trial, Wilding et al., NEJM 2021) |
| Mechanism | Amylin/calcitonin receptor agonist | Amylin receptor agonist (short-acting) | GLP-1 receptor agonist |
| Half-life | ~7 days | ~48-90 minutes | ~7 days |
| GI side effects | Moderate (nausea, vomiting) | High (nausea at initiation, 30%+) | Moderate (nausea, vomiting) |
| Legal access for non-trial patients | None (US, EU) | Prescription (diabetes indication only) | Prescription |
| Cost/accessibility | Not commercially available | Limited availability, high cost | High (list price ~$1,300/month in US) |
| Where cagrilintide loses | No approval, no long-term safety data, no legal access | Approved and accessible for indicated patients | More weight loss as monotherapy; approved and insurable |
Honest assessment: For anyone who can access semaglutide legally, it currently wins on every practical criterion: regulatory status, safety database, prescriber familiarity, and insurance coverage. Cagrilintide's clinical value proposition depends on the combination story with semaglutide, not on standalone use.
What side effects are dose-dependent and how should doses be adjusted?
In the phase 2 trial (Lau et al., 2021), GI adverse events were the most common reason for discontinuation and were clearly dose-related. The following were reported across dose arms:
- Nausea: Most frequent at 2.4 mg and 4.5 mg; lowest at 0.3 mg
- Vomiting: Less common than nausea; correlated with faster escalation
- Decreased appetite: Pharmacologically expected; overlaps with intended effect
- Injection-site reactions: More common than with placebo across all doses; generally mild
- Hypoglycemia: Rare in non-diabetic subjects; relevant if combined with insulin or sulfonylureas
Dose adjustment logic used in trials: Hold escalation for four weeks if nausea or vomiting is ongoing. Step back one level if symptoms are persistent or severe. Discontinue if vomiting requires medical intervention or if the participant cannot maintain hydration.
What is not known: There are no published long-term safety data (beyond 68 weeks) for cagrilintide. Pancreatic, thyroid (C-cell), and renal effects require ongoing monitoring because amylin and calcitonin receptor signaling is present in those tissues.
How to read a COA and evaluate what you are actually getting
Because cagrilintide is not available as an approved commercial product, anyone who encounters it outside a registered trial is dealing with a research-grade or gray-market material. The following is how to evaluate the documentation:
What a legitimate COA should include
- Molecular weight confirmation: Cagrilintide has a molecular formula that reflects the amylin backbone plus the C20 fatty-diacid linker. The molecular weight should be consistent with this structure. A COA showing only a backbone mass without conjugation indicates an incomplete product.
- HPLC purity: Should state purity by area percentage at 214 nm (peptide bond absorption). Anything below 95% purity is generally considered substandard for research use.
- Endotoxin testing: LAL (limulus amebocyte lysate) or equivalent. Result should be reported in EU/mg. Injectable compounds should meet the pharmacopoeial limit for parenteral products.
- Residual solvent analysis: Relevant for lyophilized material; should reference ICH Q3C limits.
- Issuing lab accreditation: ISO 17025 accreditation is the standard for analytical testing labs. A COA from a non-accredited in-house lab has no independent verification.
What degraded cagrilintide may look like
Intact lyophilized peptide is typically a white to off-white powder. Discoloration (yellow or brown), visible aggregates after reconstitution, or cloudiness in what should be a clear solution all suggest degradation. Peptide aggregation is particularly concerning for amylin analogues because amylin itself is amyloidogenic; aggregated material can have altered pharmacokinetics and immunogenic potential. Degradation is accelerated by heat, freeze-thaw cycling, and exposure to light.
Reconstitution: the concentration problem
In trials, cagrilintide was formulated at a defined mg/mL concentration in a pre-filled device. If you receive a vial labeled "5 mg" and reconstitute in 1 mL of bacteriostatic water, you have a 5 mg/mL solution. A 0.25 mg starting dose would require injecting 0.05 mL (50 microliters). Errors of even 0.05 mL in a small-volume syringe represent a 100% dose error. At higher concentrations, always use an insulin syringe with sub-microliter graduations and double-check math before each injection.
FAQ
What is the starting dose of cagrilintide?
In the SCALE-TRIO and CagriSema phase 3 trials, cagrilintide was initiated at 0.25 mg subcutaneously once weekly and escalated every four weeks. This mirrors the dose-escalation logic used for semaglutide to limit gastrointestinal side effects during titration.
What is the maintenance dose of cagrilintide?
The target maintenance dose used in phase 3 trials is 2.4 mg once weekly. Some participants in earlier dose-finding studies received up to 4.5 mg weekly, but 2.4 mg is the dose selected for the co-formulation with semaglutide (CagriSema) in ongoing registration trials.
How long does the cagrilintide dose escalation take?
At the standard four-week step interval (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg), full maintenance dose is reached by approximately week 16 to 20. Individual tolerability may require extending any step.
Can cagrilintide be dosed more than once a week?
No. Cagrilintide has a half-life of approximately seven days, making it suitable only for once-weekly subcutaneous dosing. More frequent dosing would cause accumulation and increase adverse event risk without adding benefit.
What is the maximum cagrilintide dose studied in humans?
A phase 2 dose-ranging trial (Lau et al., Lancet 2021) tested doses up to 4.5 mg weekly. The 2.4 mg dose was selected for phase 3 based on the benefit-risk profile: meaningful weight loss with an acceptable gastrointestinal side-effect rate.
Is cagrilintide dosage the same when combined with semaglutide?
In the CagriSema fixed-ratio co-formulation, cagrilintide 2.4 mg is combined with semaglutide 2.4 mg in one weekly injection. Each component follows its own escalation logic within the combined product, starting at lower doses and stepping up over roughly 16 weeks.
What does cagrilintide do mechanistically that justifies this dose range?
Cagrilintide activates calcitonin gene-related peptide (CGRP) and calcitonin receptors in the area postrema and nucleus tractus solitarius. It slows gastric emptying, reduces food intake, and acts centrally to increase satiety. The weekly dose is sized to maintain sustained receptor occupancy given the roughly seven-day half-life.
What are the most common side effects at higher cagrilintide doses?
Nausea, vomiting, decreased appetite, and injection-site reactions are most common and are dose-dependent. In the phase 3 SCALE-TRIO trial, gastrointestinal adverse events were the leading reason for dose reduction or discontinuation, occurring more frequently at doses above 1.7 mg weekly.
Can the cagrilintide dose be reduced if side effects occur?
Yes. Clinical trial protocols allow stepping back one dose level for persistent nausea, vomiting, or other intolerable GI events. Some participants in the phase 3 program maintained a lower maintenance dose (1.7 mg or 1.0 mg) rather than escalating to 2.4 mg.
Is cagrilintide FDA approved?
As of May 2026, cagrilintide as a standalone agent and the CagriSema co-formulation have not received FDA approval. Both are in late-stage clinical development by Novo Nordisk. Cagrilintide is not legally available as a compounded preparation in the United States under current FDA guidance.
How is cagrilintide administered?
Subcutaneous injection, once weekly, into the abdomen, thigh, or upper arm. Injection sites should be rotated. In clinical trials it was supplied as a pre-filled pen device at fixed concentrations; reconstituted powder formulations are not part of the approved investigational protocol.
How does cagrilintide dosage compare to pramlintide dosage?
Pramlintide, the only approved amylin analogue, is dosed in micrograms two to three times daily (60-120 mcg per injection for type 2 diabetes). Cagrilintide's fatty-acid conjugation extends its half-life from under two hours to approximately seven days, enabling weekly milligram-range dosing. The two are not dose-interchangeable.
Sources
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in adults with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10300):579-589.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. (STEP 1 trial; comparator reference)
- Novo Nordisk A/S. REDEFINE 1 phase 3 trial data (CagriSema). Presented at American Diabetes Association Scientific Sessions, June 2024. (Conference presentation; full publication pending as of May 2026)
- Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol. 2018;175(1):3-17. (Receptor biology reference)
- Reidelberger RD, Haver AC, Apenteng BA, et al. Effects of amylin on food intake and body weight in rats. Am J Physiol Regul Integr Comp Physiol. 2004;286(3):R429-R437. (Amylin mechanism background)
- U.S. Food and Drug Administration. Pramlintide (Symlin) prescribing information. Current label via DailyMed. (Approved amylin analogue comparator)
- Novo Nordisk A/S. ClinicalTrials.gov: NCT05536804 (REDEFINE 1) and NCT05669755 (SCALE-TRIO). Accessed May 2026.
Disclaimers
Platform: FormBlends is an informational platform. Nothing on this page constitutes medical advice, a diagnosis, or a treatment recommendation. Consult a licensed healthcare provider before making any medication or supplementation decision.
Research Compound: Cagrilintide is an investigational compound. It is not approved by the FDA or EMA as of the date of publication. Information presented here describes the investigational protocol studied in clinical trials and does not represent prescribing guidance.
Results: Weight-loss percentages cited are from controlled clinical trials with specific dietary and lifestyle interventions. Individual results outside those conditions will differ. Trial outcomes do not predict individual response.
Trademark: CagriSema, Wegovy, Symlin, and all other brand names referenced are trademarks of their respective owners. FormBlends has no commercial relationship with Novo Nordisk or any other pharmaceutical manufacturer referenced on this page.